We sought to examine signaling activation in the context of acquired resistance to the anti-EGFR antibody, cetuximab, in the previously described squamous head and neck carcinoma line UMSCC6 (University of Michigan squamous cell carcinoma) [23]. The gene discussed is EGFR; the disease is squamous cell carcinoma.